Sanofi anticipates growing portfolio in coming years

Key takeaways:

• The company plans to focus on developing its portfolio of 12 new molecular entities.
• The company expects recently launched and future pharma assets to generate more than 10 billion euros in annual sales by 2030.

Sanofi has released updates and insight into its innovation pipeline and new growth drivers, the company announced in a press release.

On Dec. 6, Sanofi held an Investor Research & Development Event in New York where it announced updates to its pipeline for the coming year.

“Building on our successful recent launches, we are making decisive choices to deliver breakthrough medicines and long-term value for all of our stakeholders,” Paul Hudson, CEO of Sanofi, said in the release. “We are confident in our current product portfolio and the strength of our pipeline to deliver sustainable growth through 2030 and beyond.”

The company plans to focus on developing its portfolio comprised of 12 new molecular entities that include multiple late-state assets. Additionally, Sanofi has announced that it hopes to expand into new indications.

According to the press release, the company expects recently launched and future pharma assets to generate more than 10 billion euros of annual sales by 2030, which will be driven by amlitelimab, frexalimab, itepekimab and tolebrutinib, in addition to Sanofi’s recently launched products, Altuviiio (efanesoctocog alfa), Sarclisa (isatuximab-irfc) and Tzield (teplizumab-mzwv).

The company also anticipates that Dupixent (dupilumab) will continue its strong performance.

The company’s research and development department plans to increase the number of phase 3 studies conducted by 50% between 2023 and 2025. The department will also support 25 mid- to late-stage read-outs and up to 19 regulatory submissions throughout the upcoming 2 years.